Docket # 03N.0168

FDA and Consumer Medication Information (CMI)

Paul J. Seligman M.D., M.P.H. Tom McGinnis, R. Ph. July 31, 2003

FD/A

August 24, 1995

- FDA publishes Medication Guide Proposed Rule for drugs with serious and significant side effects
- Proposal sets distribution targets of 75% and 95% by 2000 and 2006 for private sector
- · FDA proposes broad criteria to judge written information as being useful

FD/A

FD/A

· ·

1996 Events

- February 14 and 15 FDA convenes workshop on the medication guide proposal, specifically related to defining useful information
- · August 29 Congress passed and President signed Public Law 104-180

FD/A

Public Law 104-180

- · Directs Secretary of HHS to facilitate development of a long-range action plan that meets stated goals through private sector efforts
- · Gives private sector opportunity to meet distribution and quality standards of plan
- Codifies FDA's distribution and quality goals of 75% by 2000 and 95% by 2006

03N-0168

1

FD/A

FD/A

Keystone Center

- Secretary immediately contracts with the Keystone Center
 - non-profit consensus-building alternate dispute resolution organization
- There were 120 days under the statute to facilitate development of an action plan by interested stakeholders
- Keystone selected 34 private sector organizations to develop the Action Plan

FD/A

FD/A

Action Plan

- Collaboratively developed plan accepted by the Secretary in January 1997
- Criteria to determine usefulness
 - endorsed broad criteria in the public law
 - described specific criteria to be met
- Consistent with the public law, the plan called for periodic assessment of the quality of written information

Criteria for Useful Medication Information

- 1. Drug Names, indications for use
- 2. Contraindications, what to do
- 3. How to use, monitor, and get most benefit for drug
- 4. Precautions, how to avoid harm

Criteria for Useful Medication Information

- 5. Serious or frequent adverse reactions, what to do
- 6. General information, encouragement to ask questions
- 7. Scientifically accurate, not promotional, and up-to-date
- 8. Comprehensible (6-8th grade), legible

1998 - FDA Publishes Final Medication Guide Rule

- December 1 Final Rule is published
- Rule estimates 5-10 products per year could have a Medication Guide
- Medication Guide reserved for drugs with serious and significant side effects
- To date, FDA has required 15 Medication Guides for prescription drug and biologics

June 2000 FDA Begins Plan for First Assessment

• FDA renews contract with NABP and University of Wisconsin School of Pharmacy for evaluation phase

FD/A

- 384 pharmacies randomly selected from virtually every state
- Professional shopping service selected to buy four prescription drugs and collect data

2001 National Evaluation


- Same evaluation methods as 1999 pilot study
- NABP and subcontractor sampled > 1300 CMI brochures
- · Brochures evaluated by expert panel
 - Pharmacy
 - Medical Information
 - Drug Information

2001 National Evaluation

Endpoints:

FD/A

- Distribution
- Usefulness of each material via eight criteria



• • •

FD/A

FDA's Approach Post-AC

- AC asks FDA to take a more active role
- FDA defers decision on regulatory action

 voluntary process can work if action begins
 now

Areas That Need Consensus/Action (I)

- Implementation
- Education

FD/A

• Evaluation

Areas That Need Consensus/Action (II)

- Implementation
 - major quality improvements needed
 - identify procedures that will allow clear understanding of what is required
- Education

FD/A

 lack of awareness of Keystone criteria and legislative requirement for CMI educate "information developers," software vendors, prof'l associations, pharmacies, etc

Areas That Need Consensus/Action (III)

• Evaluation: clarification of how the Keystone criteria will be applied to specific drug products in the future

FD/A

FDA Commissioner McClellan

- Very supportive of this effort
- Speech to National Consumer League February 28, 2003
 - communicating risk information about Rx medicines is one of his highest priorities

FD/A

FD/A

•

Next Steps

- Current need: plans for action to meet 2006 target
- Plans should include:
 - roles and responsibilities clearly articulated for all groups
 - identified barriers and what will be done to overcome them

FD/A

Questions for Today's Meeting

• 1: What steps is the private sector taking to improve the usefulness of the written information patients receive with prescription drugs and to meet the Year 2006 goal?

FD/A

•

Questions for Today's Meeting

- 2: What barriers exist for the private sector to meet the Year 2006 goal, and what plans exist to overcome these barriers?
- 3: What should the role of FDA be in assuring full implementation of the Action Plan to meet the Year 2006 goal?

FD/A

Questions for Today's Meeting

• 4: What other initiatives should FDA consider for providing patients with useful written information about prescription drugs as endorsed by P.L. 104-180?